Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115245) titled 'Observational Study on Dose Optimization of Olverembatinib in Patients with Chronic Myeloid Leukemia in Chronic or Accelerated Phase' on Dec. 24, 2025.
Study Type: Observational study
Study Design:
Single arm
Primary Sponsor: Peking University People's Hospital
Condition:
Chronic myeloid leukemia
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2025-12-25
Target Sample Size: Olverembatinib dose adjustment group:100;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=302319
Published by HT Digital Content Services with permission ...